Results 11 to 20 of about 27,000 (252)

Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know

Reviews in Cardiovascular Medicine, 2023
Chemotherapies have changed the prognosis of patients affected by cancer over the last 20 years, with a significant increase in survival rates. However, they can cause serious adverse effects that may limit their use.
Armando Ferrera, Vincenzo Fiorentini, Simone Reale, Giorgio Solfanelli, Giacomo Tini, Emanuele Barbato, Massimo Volpe, Allegra Battistoni   +7 more
doaj   +1 more source

Anthracyclines and trastuzumab associated cardiotoxicity: is the gut microbiota a friend or foe? – a mini-review

Frontiers in Microbiomes, 2023
Breast cancer (BC) is one of the most prevalent cancers worldwide. Fortunately, BC treatment has taken a huge turn in the last few years. Despite these advances, one of the main issues related to systemic treatment remains the management of its side ...
J. Guilherme Gonçalves-Nobre, J. Guilherme Gonçalves-Nobre, J. Guilherme Gonçalves-Nobre, J. Guilherme Gonçalves-Nobre, Inês Gaspar, Diogo Alpuim Costa, Diogo Alpuim Costa, Diogo Alpuim Costa   +7 more
doaj   +1 more source

In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics

Molecules, 2023
Anthracycline antibiotics (ANT) are among the most widely used anticancer drugs. Unfortunately, their use is limited due to the development of drug resistance and cardiotoxicity.
Marek Jamrozik, Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Michał Sapa, Benedykt Władyka, Elżbieta Pękala, Marcin Kołaczkowski   +7 more
doaj   +1 more source

Cardiac Events in Childhood Cancer Survivors Treated with Anthracyclines: The Value of Previous Myocardial Strain Measurement

Life, 2022
In echocardiographic surveillance of anthracycline-treated childhood cancer survivors (CCS), left ventricular ejection fraction (LVEF) has insufficient prognostic value for future cardiac events, whereas longitudinal strain may be more sensitive.
Milanthy Pourier, Remy Merkx, Jacqueline Loonen, Alyssa van Cleef, Chris de Korte, Louise Bellersen, Livia Kapusta, Annelies Mavinkurve-Groothuis   +7 more
doaj   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

Mitochondria Death/Survival Signaling Pathways in Cardiotoxicity Induced by Anthracyclines and Anticancer-Targeted Therapies

Biochemistry Research International, 2012
Anthracyclines remain the cornerstone of treatment in many malignancies but these agents have a cumulative dose relationship with cardiotoxicity. Development of cardiomyopathy and congestive heart failure induced by anthracyclines are typically dose ...
David Montaigne, Christopher Hurt, Remi Neviere   +2 more
doaj   +1 more source

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor

Chinese Medical Journal, 2018
Background: Cardiotoxicity is one of the most serious chronic complications of anthracyclines therapy. Assessment of the left ventricular ejection fraction (LVEF) fails to detect subtle cardiac dysfunction of left ventricular (LV).
Hui-Min Hu, Xiao-Lin Zhang, Wei-Ling Zhang, Dong-Sheng Huang, Zhong-Dong Du   +4 more
doaj   +1 more source

Anthracycline Cardiotoxicity in Children [PDF]

New England Journal of Medicine, 2004
More than 70 percent of children who are treated for childhood cancer can be cured. For long-term survivors, possible late effects of treatment and their consequences for the quality of life are a major concern. Cardiotoxic effects of anthracyclines are among the most frequent and serious adverse effects of the treatment of childhood cancer ...
Kremer, L.C.M., Caron, H.N.
openaire   +5 more sources

Uptake Assays to Monitor Anthracyclines Entry into Mammalian Cells

Bio-Protocol, 2017
Anthracyclines, such as doxorubicin and daunorubicin, are DNA damaging agents that autofluoresce and can be readily detected in cells. Herein, we developed suitable assays to quantify and localize daunorubicin in mammalian cells.
Nicolas Brosseau, Emil Andreev, Dindial Ramotar   +2 more
doaj   +1 more source

Efficacy of Physical Exercise to Offset Anthracycline‐Induced Cardiotoxicity: A Systematic Review and Meta‐Analysis of Clinical and Preclinical Studies

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Physical exercise is an intervention that might protect against doxorubicin‐induced cardiotoxicity. In this meta‐analysis and systematic review, we aimed to estimate the effect of exercise on doxorubicin‐induced cardiotoxicity and to evaluate ...
Willeke R. Naaktgeboren, David Binyam, Martijn M. Stuiver, Neil K. Aaronson, Arco J. Teske, Wim H. van Harten, Wim G. Groen, Anne M. May   +7 more
doaj   +1 more source